Latham counsels Avalanche Biotechnologies in $142 million financing
Latham & Watkins represented Menlo Park-based Avalanche Biotechnologies Inc. in its $141.6 million follow-on offering of 2,399,457 shares of common stock at $59 per share. Of the total number of shares, 2,009,457 are being offered by Avalanche, while the remaining 390,000 are being offered by existing shareholders.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
